Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

29.10.2020 | review

Fertility preservation in women with endometrial cancer

verfasst von: Helena Bralo, MD, Maria Roethlisberger, MD, Assoc. Prof. Kazem Nouri, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Summary

Fertility preservation should only be offered to patients with endometrial cancer stage Ia grade 1 (G1), who present without myometrial invasion or where the cancer has invaded less than 50% of the myometrium, with no evidence of pathological lymph nodes or no evidence of synchronous or metachronous ovarian tumor. It is estimated that about 22% will achieve successful pregnancy.
Vorheriger Artikel Future perspectives of fertility preservation in women
Nächster Artikel Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer
Literatur
1.
2.
3.
4.
Guillon S, Popescu N, Phelippeau J, Koskas M. A systematic review and meta-analysis, of prognostic factors for remission in fertility sparingmanagement of endometrialatypical hyperplasia and adenocarcinoma. Int J Gynecol Obstet. 2019; https://​doi.​org/​10.​1002/​ijgo.​12882.CrossRef
5.
6.
Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64:417–20.PubMed
7.
Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105:575–80.CrossRef
8.
Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327–31.CrossRef
9.
Tran BN, Connell PP, Waggoner S, et al. Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. Am J Clin Oncol. 2000;23:476–80.CrossRef
10.
Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651–7.CrossRef
11.
Duska LR, Garrett A, Rueda BR. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83:388–93.CrossRef
12.
Huang SY, Jung SM, Ng KK, et al. Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol. 2005;97:652–5.CrossRef
13.
National Institute for Health and Clinical Excellence CG44. Heavy menstrual bleeding. 2007.
14.
American College of Obstetricians and Gynecologists. Practice bulletin. Diagnosis of abnormal uterine bleeding in reproductive aged women. Obstet Gynecol. 2012;128:1–11.
15.
Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017;124:404–11.CrossRef
16.
17.
Walsh C, Holschneider C, Hoang Y. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106:693–9.CrossRef
18.
Morice P, Fourchotte V, Sideris L. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol. 2005;96:245–8.CrossRef
19.
Zarbo G, Caruso G, Caruso S, Mangano U, Zarbo R. Endometrial cancer: preoperative evaluation of myometrial infiltration magnetic resonance imaging versus transvaginal ultrasonography. Eur J Gynaecol Oncol. 2000;21(1):95–7. PMID: 10726632.PubMed
20.
Nouri K, Reinthaller A. Fertilitätserhalt bei prämenopausalen Frauen mit # Endometriumkarzinom im frühen, niedriggradigen Stadium. Speculum. 2015;33(1):12–6.
21.
Cosgrove CM, Cohn DE, Hampel H, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol Oncol. 2017;146:588–95.CrossRef
22.
Cohn DE, Frankel WL, Resnick KE, et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol. 2006;108:1208–15.CrossRef
23.
Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review. Medicine (Baltimore). 2017;96:e8034.CrossRef
24.
Son J, Carr C, Yao M, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years. Int J Gynecol Cancer. 2020;30:631–9.CrossRef
25.
Harrison RF, He W, Fu S, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer oratypical hyperplasia. Am J Obstet Gynecol. 2019;221:474.e1–11.
26.
Mazzon I, Corrado G, Masciullo V, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286–9.CrossRef
27.
28.
Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207:266.e1–266.e12.CrossRef
29.
30.
Shih KK, Garg K, Levine DA, et al. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40 years of age and younger. Gynecol Oncol. 2011;123:88–94.CrossRef
Metadaten
Titel
Fertility preservation in women with endometrial cancer
verfasst von
Helena Bralo, MD
Maria Roethlisberger, MD
Assoc. Prof. Kazem Nouri, MD
Publikationsdatum
29.10.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00661-6

Weitere Artikel der Ausgabe 4/2020

Ovarian transposition

  • Open Access
  • short review

A case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature

  • Open Access
  • case report

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer with peritoneal metastasis: Status quo and how should we proceed

  • editorial

Molecular profiling in breast cancer—ready for clinical routine?

  • Open Access
  • short review

Homologous recombination deficiency: New biomarkers in innovative treatments

  • editorial

Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?

  • Open Access
  • short review